We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Prior to joining Immunocore, Berman served as senior vice president and head of AstraZeneca's immuno-oncology franchise, holding responsibility for the strategy and execution of the drugmaker's late-stage immuno-oncology programme.
Three years after closing a record-breaking $320m private financing Immunocore is having a personnel crisis. The shock departure in February of its chief executive, Eliot Forster, has had a contagious effect, with various other execs, including chief medi
It has been announced that the Bill & Melina Gates Foundation will invest up to $40 million in UK-based Immunocore to support the development of therapeutics for infectious diseases.